The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE^-/- mice and inhibits monocyte/macrophage recruitment

Summary

We showed previously that reduced level of vasostatin-2 (VS-2) correlates to the presence and severity of coronary artery disease. In this study, we aimed to figure out the role of chromogranin A (CGA) derived VS-2 in the development of atherosclerosis and monocyte/macrophage recruitment. Apolipoprotein E-deficient (ApoE^-/-) mice fed a high-fat diet exhibited attenuated lesion size by 65 % and 41 % in En face and aortic root Oil red O staining, MOMA-2 positive area by 64 %, respectively, in VS-2 treatment group compared with PBS group. Proinflammatory cytokines tumour necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) were all remarkably reduced in aortic tissues after VS-2 treatment. Mechanistically, in adhesion assay using intravital microscopy in vivo, VS-2 suppressed the number of leukocytes adhering to the wall of apoE^-/- mice mesenteric arteries. In chemotactic assay, flow cytometry analysis of peritoneal lavage exudate from C57BL/6 mice showed VS-2 significantly decreased the recruiment number of inflammatory monocytes/macrophages in a thioglycollate-induced peritonitis model. Furthermore, fewer fluorescent latex beads labelled Ly-6C^hi monocytes accumulated in aortic sinus lesions of apoE^-/- mice after VS-2 treatment. In addition, according to the microarray of human monocyte/macrophage, we found VS-2 stimulation caused a dose-dependent decrease of Rac1 expression and inactivation of Pak1 in mice primary monocytes as well as THP-1 cells and inhibited MCP-1/CCL-5 induced transmigration in vitro. In conclusion, the Chromogranin A-derived VS-2 attenuates atherosclerosis in apoE^-/- mice and, in addition to its anti-inflammatory property, also acts as an inhibitor in monocyte/macrophage recruitment.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Atherosclerosis - monocytes - chemotaxis - inflammation - vasostatin-2

• References

• 1 Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscl Thromb Vasc Biol 2009; 29: 1412-1418.
• 2 Farb A, Burke AP, Tang AL. et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.. Circulation 1996; 93: 1354-1363.
• 3 Swirski FK, Pittet MJ, Kircher MF. et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease.. Proc Natl Acad Sci USA 2006; 103: 10340-10345.
• 4 Potteaux S, Gautier EL, Hutchison SB. et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression.. J Clin Invest 2011; 121: 2025-2036.
• 5 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Med 2011; 17: 1410-1422.
• 6 Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nature Rev Immunol 2013; 13: 709-721.
• 7 Tacke F, Alvarez D, Kaplan TJ. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.. J Clin Invest 2007; 117: 185-194.
• 8 Swirski FK, Libby P, Aikawa E. et al. Ly-6Chi monocytes dominate hypercholesterolaemia-associated monocytosis and give rise to macrophages in atheromata.. J Clin Invest 2007; 117: 195-205.
• 9 Combadiere C, Potteaux S, Rodero M. et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolaemic mice.. Circulation 2008; 117: 1649-1657.
• 10 Aflaki E, Balenga NA, Luschnig-Schratl P. et al. Impaired Rho GTPase activation abrogates cell polarisation and migration in macrophages with defective lipolysis.. Cell Mol Life Sci 2011; 68: 3933-3947.
• 11 Nakamura F. FilGAP and its close relatives: a mediator of Rho-Rac antagonism that regulates cell morphology and migration. Biochem J 2013; 453: 17-25.
• 12 Singh NK, Kotla S, Dyukova E. et al. Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice.. Nature Commun 2015; 06: 7450.
• 13 Smith SD, Jaffer ZM, Chernoff J. et al. PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics.. J Cell Sci 2008; 121: 3729-3736.
• 14 Jhaveri KA, Debnath P, Chernoff J. et al. The role of p21-activated kinase in the initiation of atherosclerosis.. BMC Cardiovasc Disord 2012; 12: 55.
• 15 Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-1149.
• 16 Brekke JF, Osol GJ, Helle KB. N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. Regul Peptides 2002; 105: 93-100.
• 17 Cerra MC, Gallo MP, Angelone T. et al. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide.. FASEB J 2008; 22: 3992-4004.
• 18 Blois A, Srebro B, Mandala M. et al. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells.. Regul Peptides 2006; 135: 78-84.
• 19 Huegel R, Velasco P, De la Luz Sierra M. et al. Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin.. J Invest Dermatol 2007; 127: 65-74.
• 20 Lu L, Wang YN, Li MC. et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease.. Eur Heart J 2012; 33: 2297-2306.
• 21 Roatta S, Passatore M, Novello M. et al. The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit.. Regul Peptides 2011; 168: 10-20.
• 22 Rensing KL, de Jager SC, Stroes ES. et al. Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice.. Cardiovasc Res 2014; 101: 277-287.
• 23 Kuhnast S, van der Tuin SJ, van der Hoorn JW. et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.. Eur Heart J 2015; 36: 39-48.
• 24 Wadsworth MP, Sobel BE, Schneider DJ. et al. Quantitative analysis of atherosclerotic lesion composition in mice.. Methods Mol Biol 2006; 319: 137-152.
• 25 Ni W, Egashira K, Kitamoto S. et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice.. Circulation 2001; 103: 2096-2101.
• 26 Ying W, Cheruku PS, Bazer FW. et al. Investigation of macrophage polarisation using bone marrow derived macrophages.. J Visual Exp 2013; 76: e50323.
• 27 Wang XQ, Nigro P, World C. et al. Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2.. Circ Res 2012; 110: 560-568.
• 28 Han KH, Hong KH, Park JH. et al. C-reactive protein promotes monocyte chemoattractant protein-1--mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes.. Circulation 2004; 109: 2566-2571.
• 29 Medina I, Cougoule C, Drechsler M. et al. Hck/Fgr Kinase Deficiency Reduces Plaque Growth and Stability by Blunting Monocyte Recruitment and Intraplaque Motility.. Circulation 2015; 132: 490-501.
• 30 Namiki M, Kawashima S, Yamashita T. et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolaemia.. Arterioscl Thromb Vasc Biol 2002; 22: 115-120.
• 31 Orr AW, Stockton R, Simmers MB. et al. Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesis.. J Cell Biol 2007; 176: 719-727.
• 32 Soehnlein O, Drechsler M, Doring Y. et al. Distinct functions of chemokine receptor axes in the atherogenic mobilisation and recruitment of classical monocytes.. EMBO Mol Med 2013; 05: 471-481.
• 33 Libby P, Aikawa M. Stabilisation of atherosclerotic plaques: new mechanisms and clinical targets. Nature Med 2002; 08: 1257-1262.
• 34 Di Comite G, Morganti A. Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems. J Hypertension 2011; 29: 409-414.
• 35 Colombo B, Longhi R, Marinzi C. et al. Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion.. J Biol Chem 2002; 277: 45911-45919.
• 36 Ferrero E, Scabini S, Magni E. et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.. FASEB J 2004; 18: 554-556.
• 37 Gautier EL, Huby T, Witztum JL. et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage.. Circulation 2009; 119: 1795-1804.